In: Stem Cell Research & Therapy, 6 (2015), Nr. 236. pp. 1-11. ISSN 1757-6512
Preview |
PDF, English
Download (3MB) | Lizenz: Creative Commons Attribution 3.0 Germany |
Abstract
The inherent immunomodulatory capacity of mesenchymal stem/progenitor cells (MSPCs) encouraged initiation of multiple clinical trials. Release criteria for therapeutic MSPCs cover identity, purity and safety but appropriate potency assessment is often missing. Reports on functional heterogeneity of MSPCs created additional uncertainty regarding donor and organ/source selection. We established a robust immunomodulation potency assay based on pooling responder leukocytes to minimize individual immune response variability. Comparing various MSPCs revealed significant potency inconsistency and generally diminished allo-immunosuppression compared to dose-dependent inhibition of mitogenesis. Gamma-irradiation to block unintended MSPC proliferation did not prohibit chondrogenesis and osteogenesis in vivo, indicating the need for alternative safety strategies.
Document type: | Article |
---|---|
Journal or Publication Title: | Stem Cell Research & Therapy |
Volume: | 6 |
Number: | 236 |
Publisher: | BioMed Central |
Place of Publication: | London |
Date Deposited: | 08 Feb 2016 13:59 |
Date: | 2015 |
ISSN: | 1757-6512 |
Page Range: | pp. 1-11 |
Faculties / Institutes: | Medizinische Fakultät Mannheim > Institut für Transfusionsmedizin und Immunologie |
DDC-classification: | 570 Life sciences |